The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound from its preferred list, making rival ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

CVS Health selected former Eli Lilly CFO Derica Rice to serve as the president of its pharmacy benefit management division, CVS Caremark, according to The Wall Street Journal. Effective March 30 ...

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities through a program with the U.S. government’s Operation Warp Speed ...

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities through a program with the U.S. government’s Operation Warp Speed ...